Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2022 Feb 18;205(10):1243–1245. doi: 10.1164/rccm.202111-2496LE

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 by the American Thoracic Society

This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0. For commercial usage and reprints, please e-mail Diane Gern (dgern@thoracic.org).

PMC Copyright notice

Figure 1. — (A) Time after dose 2 of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccination and IgG titer to wild-type SARS-CoV-2 receptor-binding domain (RBD). Shaded area indicates 95% confidence interval. Treatment group includes all patients on benralizumab, dupilumab, and mepolizumab. (B) IgG to wild-type SARS-CoV-2 RBD on Days 25–49, 50–74, and 75–99 after dose 2 of the SARS-CoV-2 mRNA vaccine. Treatment group includes all patients on benralizumab, dupilumab, and mepolizumab; *P < 0.012 and ***P = 0.0001. MFI = median fluorescence intensity.